Iovance Biotherapeutics targets significant market expansion, with lung cancer representing a $10B U.S. peak sales ...
NDA supported by results from a Phase II registration trial in China —— Second most common form of liver cancer after hepatocellular carcinoma, ...
BARC has opened Scientific Officer recruitment 2026 under OCES and DGFS, offering high salary, structured training and Group ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback